Share on LinkedInShare on LinkedIn

ARTICLE · 20 OCTOBER 2017

PTAB Declines Request To Review Method Of Treating Lymphoma Claim

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

There was also no evidence to show that an interested party would have known to visit a particular oncology website to look for the consent form.

United StatesIntellectual Property

A Patent Trial and Appeal Board (PTAB) panel declined to institute an inter partes review (IPR) of a claim directed to a method for treating low grade B-cell non-Hodgkin's lymphoma. The challenged method required patients to be treated with cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy, followed by four once-weekly doses of 375 mg/m2rituximab, an anti-CD20 antibody, every six months for two years.

In rejecting petitioner's anticipation and obviousness challenges, the panel found that several asserted references were not publicly accessible and, therefore, did not qualify as "printed publications." First, although a clinical study consent form was distributed to approximately 40 prospective patients, there was no evidence that it was distributed to ordinarily skilled artisans, rather than patients. There was also no evidence to show that an interested party would have known to visit a particular oncology website to look for the consent form.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from